Literature DB >> 11483779

Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro.

P W Parren1, P A Marx, A J Hessell, A Luckay, J Harouse, C Cheng-Mayer, J P Moore, D R Burton.   

Abstract

A major unknown in human immunodeficiency virus (HIV-1) vaccine design is the efficacy of antibodies in preventing mucosal transmission of R5 viruses. These viruses, which use CCR5 as a coreceptor, appear to have a selective advantage in transmission of HIV-1 in humans. Hence R5 viruses predominate during primary infection and persist throughout the course of disease in most infected people. Vaginal challenge of macaques with chimeric simian/human immunodeficiency viruses (SHIV) is perhaps one of the best available animal models for human HIV-1 infection. Passive transfer studies are widely used to establish the conditions for antibody protection against viral challenge. Here we show that passive intravenous transfer of the human neutralizing monoclonal antibody b12 provides dose-dependent protection to macaques vaginally challenged with the R5 virus SHIV(162P4). Four of four monkeys given 25 mg of b12 per kg of body weight 6 h prior to challenge showed no evidence of viral infection (sterile protection). Two of four monkeys given 5 mg of b12/kg were similarly protected, whereas the other two showed significantly reduced and delayed plasma viremia compared to control animals. In contrast, all four monkeys treated with a dose of 1 mg/kg became infected with viremia levels close to those for control animals. Antibody b12 serum concentrations at the time of virus challenge corresponded to approximately 400 (25 mg/kg), 80 (5 mg/kg), and 16 (1 mg/kg) times the in vitro (90%) neutralization titers. Therefore, complete protection against mucosal challenge with an R5 SHIV required essentially complete neutralization of the infecting virus. This suggests that a vaccine based on antibody alone would need to sustain serum neutralizing antibody titers (90%) of the order of 1:400 to achieve sterile protection but that lower titers, around 1:100, could provide a significant benefit. The significance of such substerilizing neutralizing antibody titers in the context of a potent cellular immune response is an important area for further study.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11483779      PMCID: PMC115078          DOI: 10.1128/jvi.75.17.8340-8347.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

1.  Preferential coreceptor utilization and cytopathicity by dual-tropic HIV-1 in human lymphoid tissue ex vivo.

Authors:  S Glushakova; Y Yi; J C Grivel; A Singh; D Schols; E De Clercq; R G Collman; L Margolis
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

Review 2.  HIV-1 entry at the mucosal surface: role of antibodies in protection.

Authors:  J R Mascola; S S Frankel; K Broliden
Journal:  AIDS       Date:  2000       Impact factor: 4.177

Review 3.  Erratum to "Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design".

Authors:  P W Parren; M C Gauduin; R A Koup; P Poignard; Q J Sattentau; P Fisicaro; D R Burton
Journal:  Immunol Lett       Date:  1997-07       Impact factor: 3.685

4.  Identification and characterization of a peptide that specifically binds the human, broadly neutralizing anti-human immunodeficiency virus type 1 antibody b12.

Authors:  M B Zwick; L L Bonnycastle; A Menendez; M B Irving; C F Barbas; P W Parren; D R Burton; J K Scott
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

5.  Immunoglobulin concentrations and antigen-specific antibody levels in cervicovaginal lavages of rhesus macaques are influenced by the stage of the menstrual cycle.

Authors:  F X Lü; Z Ma; T Rourke; S Srinivasan; M McChesney; C J Miller
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

6.  A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals.

Authors:  D R Burton; C F Barbas; M A Persson; S Koenig; R M Chanock; R A Lerner
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-15       Impact factor: 11.205

7.  Secretory immunity in the female reproductive tract.

Authors:  W H Kutteh; J Mestecky
Journal:  Am J Reprod Immunol       Date:  1994-01       Impact factor: 3.886

8.  Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats.

Authors:  G A Prince; R L Horswood; R M Chanock
Journal:  J Virol       Date:  1985-09       Impact factor: 5.103

9.  Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.

Authors:  P Roben; J P Moore; M Thali; J Sodroski; C F Barbas; D R Burton
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

Review 10.  The antiviral activity of antibodies in vitro and in vivo.

Authors:  P W Parren; D R Burton
Journal:  Adv Immunol       Date:  2001       Impact factor: 3.543

View more
  366 in total

1.  Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5.

Authors:  C E Parker; L J Deterding; C Hager-Braun; J M Binley; N Schülke; H Katinger; J P Moore; K B Tomer
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

2.  Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody.

Authors:  Paul W H I Parren; Tom W Geisbert; Toshiaki Maruyama; Peter B Jahrling; Dennis R Burton
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

3.  Hyperimmune bovine colostrum as a low-cost, large-scale source of antibodies with broad neutralizing activity for HIV-1 envelope with potential use in microbicides.

Authors:  Marit Kramski; Rob J Center; Adam K Wheatley; Jonathan C Jacobson; Marina R Alexander; Grant Rawlin; Damian F J Purcell
Journal:  Antimicrob Agents Chemother       Date:  2012-06-04       Impact factor: 5.191

4.  An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site.

Authors:  Fatima K Ahmed; Brenda E Clark; Dennis R Burton; Ralph Pantophlet
Journal:  Vaccine       Date:  2011-12-04       Impact factor: 3.641

5.  Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1.

Authors:  Robert Pejchal; Laura M Walker; Robyn L Stanfield; Sanjay K Phogat; Wayne C Koff; Pascal Poignard; Dennis R Burton; Ian A Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-02       Impact factor: 11.205

6.  A chimeric HIV-1 envelope glycoprotein trimer with an embedded granulocyte-macrophage colony-stimulating factor (GM-CSF) domain induces enhanced antibody and T cell responses.

Authors:  Thijs van Montfort; Mark Melchers; Gözde Isik; Sergey Menis; Po-Ssu Huang; Katie Matthews; Elizabeth Michael; Ben Berkhout; William R Schief; John P Moore; Rogier W Sanders
Journal:  J Biol Chem       Date:  2011-04-22       Impact factor: 5.157

7.  Increased mucosal transmission but not enhanced pathogenicity of the CCR5-tropic, simian AIDS-inducing simian/human immunodeficiency virus SHIV(SF162P3) maps to envelope gp120.

Authors:  Mayla Hsu; Janet M Harouse; Agegnehu Gettie; Clarisa Buckner; James Blanchard; Cecilia Cheng-Mayer
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

8.  Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer.

Authors:  Anne D Lewis; Ruju Chen; David C Montefiori; Philip R Johnson; K Reed Clark
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

9.  Rapid evolution of the neutralizing antibody response to HIV type 1 infection.

Authors:  Douglas D Richman; Terri Wrin; Susan J Little; Christos J Petropoulos
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-18       Impact factor: 11.205

10.  Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies.

Authors:  John R Mascola; Mark G Lewis; Thomas C VanCott; Gabriela Stiegler; Hermann Katinger; Michael Seaman; Kristin Beaudry; Dan H Barouch; Birgit Korioth-Schmitz; Georgia Krivulka; Anna Sambor; Brent Welcher; Daniel C Douek; David C Montefiori; John W Shiver; Pascal Poignard; Dennis R Burton; Norman L Letvin
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.